Tarsus CCO awarded options and RSUs

Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala reported equity awards consisting of stock options and restricted stock units.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala reported equity awards consisting of stock options and restricted stock units. He was granted stock options for 30,724 shares at an exercise price of $0.00, and 19,306 restricted stock units, each representing one share of common stock upon vesting.

Twenty‑five percent of the option shares vest on March 5, 2027, with the remaining options vesting monthly over three years, conditioned on continued service. The 19,306 RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, also subject to his continuous service.

Insider Trade Summary

Grant/Award: 50,030 shares

Grant/Award 2 txns

Insider Mottiwala Aziz

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,724	$0.00	$0.00
Grant/Award	Restricted Stock Units	19,306	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,724 contracts (Direct); Restricted Stock Units — 19,306 contracts (Direct)

Footnotes (3)

1. F1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
2. F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
3. F3. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Tarsus Pharmaceuticals (TARS) report for Aziz Mottiwala?

Tarsus Pharmaceuticals reported that Chief Commercial Officer Aziz Mottiwala received equity awards, including stock options for 30,724 shares and 19,306 restricted stock units. Both awards vest over multiple years, contingent on his continued service with the company during the vesting period.

How many stock options were granted to the Tarsus (TARS) Chief Commercial Officer?

Aziz Mottiwala was granted stock options covering 30,724 shares of Tarsus common stock. These options have a stated price of $0.00 per share and vest 25% on March 5, 2027, with the remainder vesting monthly over the following three years.

What are the vesting terms for Aziz Mottiwala’s Tarsus (TARS) stock options?

Twenty-five percent of the 30,724 option shares vest on March 5, 2027. The remaining 75% vest in equal monthly installments over three additional years, and all vesting is conditioned on Aziz Mottiwala’s continuous service with Tarsus Pharmaceuticals.

How many restricted stock units did Tarsus (TARS) grant to Aziz Mottiwala?

Tarsus granted 19,306 restricted stock units to Aziz Mottiwala. Each RSU represents a contingent right to receive one share of common stock, subject to vesting conditions and his continued service with the company throughout the scheduled vesting dates.

When do the Tarsus (TARS) RSUs granted to Aziz Mottiwala vest?

The 19,306 RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030. Each installment requires Aziz Mottiwala to remain in continuous service with Tarsus Pharmaceuticals through the applicable vesting date.

What does each Tarsus (TARS) restricted stock unit granted to Aziz Mottiwala represent?

Each restricted stock unit granted to Aziz Mottiwala represents a contingent right to receive one share of Tarsus common stock. The units convert into shares only upon satisfying the time-based vesting schedule and the requirement that he remains employed by the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mottiwala Aziz

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$74.9	03/05/2026		A		30,724		(1)	03/04/2036	Common Stock	30,724	$0	30,724	D
Restricted Stock Units	(2)	03/05/2026		A		19,306		(3)	(3)	Common Stock	19,306	$0	19,306	D

Explanation of Responses:

1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

3. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.